What potential risks are associated with using INH in conjunction with other antituberculosis drugs?

Using isoniazid (INH) in conjunction with other antituberculosis drugs can indeed pose potential risks, particularly regarding overlapping toxicities. One of the primary concerns with INH is its hepatotoxicity, which can be exacerbated when combined with other medications that also stress the liver. Many antituberculosis drugs, such as rifampicin and pyrazinamide, can similarly affect liver function. As a result, patients undergoing treatment with multiple antituberculosis agents need careful monitoring for signs of liver damage, such as elevated liver enzymes or symptoms of liver failure.

Moreover, there can also be a concern for neurotoxicity associated with INH, particularly if concurrent medications amplify the risk of neurological side effects. For example, peripheral neuropathy can occur with INH treatment, especially if vitamin B6 levels are not adequately managed.

In contrast, while there are benefits to combining certain medications for enhancing treatment effectiveness or reducing the risk of developing drug resistance, the primary risk associated with combining INH with other antituberculosis drugs is the potential for these overlapping toxicities, making option B the most relevant and accurate in this context.